The goal of this proposal is to determine the exact roles of certain lipid second messenger molecules [i.e., diacylglycerols (DAG's)] and endogenous mediators [resolvins, docosatrienes (DT), lipoxins] in periodontal inflammation, and to continue to develop novel molecular strategies to pharmacologically interrupt the inflammatory cascade. We will focus on Localized Aggressive Periodontitis (LAP, formerly known as localized juvenile periodontitis, LJP), which presents neutrophils with a classically "primed" phenotype, i.e. hyper-responsiveness in superoxide production during cell stimulation. Neutrophils (PMN) isolated from peripheral blood of LAP patients exhibit a three fold elevation in cellular diacylglycerol and a two to three fold increase in membrane associated protein kinase (PKC) activity. A marked decrease in the alpha-isoform
of DAG kinase (DGKalpha) activity occurs in these cells, which is likely to be responsible for the elevated levels of DAG and the priming phenomena. Work by our group (see Project 0001) has revealed new classes endogenous lipid mediators (LM), the resolvins and docosatrienes (DT), which are potent natural inhibitors of inflammation in a wide variety of animal models including the rabbit model of periodontal destruction. These compounds block superoxide production and chemotaxis in stimulated PMN with certain agonists. To accomplish our goals, we will evaluate the molecular mechanisms responsible for the dramatic decrease in DGKalpha activity in LAP PMN at the genetic and biochemical level, identify the isoforms of membrane-bound PKC that are elevated in LAP PMN due to increased DAG, and determine how these elevations in DAG/membrane bound PKC "prime" the NADPH-oxidase complex to produce more superoxide/peroxide in LAP PMN. Finally, we will evaluate the beneficial effect of resolvins and docosatrienes on periodontal inflammation in situ and compare our results to those observed for lipoxins and their stable analogs.
Techniques of molecular biology, biochemistry, and animal pathophysiology will be used in these studies.
National Institute of Dental and Craniofacial Research
CFDA Code
DUNS Number
030811269
UEI
QN6MS4VN7BD1
Project Start Date
Project End Date
Budget Start Date
01-August-2005
Budget End Date
31-July-2006
Project Funding Information for 2005
Total Funding
$237,124
Direct Costs
$146,826
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Dental and Craniofacial Research
$237,124
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P50DE016191-02 0003
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P50DE016191-02 0003
Patents
No Patents information available for 5P50DE016191-02 0003
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P50DE016191-02 0003
Clinical Studies
No Clinical Studies information available for 5P50DE016191-02 0003
News and More
Related News Releases
No news release information available for 5P50DE016191-02 0003
History
No Historical information available for 5P50DE016191-02 0003
Similar Projects
No Similar Projects information available for 5P50DE016191-02 0003